Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of cryoablation plus immunochemotherapy in advanced NSCLC
ChiCTR2500107868Phase 2Not yet recruiting
- Sponsor
- Yueyang Central Hospital
- Start
- Aug 2025
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of chemotherapy + immune checkpoint inhibitors in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Yueyang Central Hospital. Primary endpoint: progression-free survival. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
chemotherapy + immune checkpoint inhibitors
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500107868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107868.